CliniExperts Successfully Completes Phase IV Akynzeo® I.V Study for Glenmark

ANI

Updated At : 10:45 AM Nov 28, 2025 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

SMPL

New Delhi [India], November 28: CliniExperts Research Services Pvt. Ltd., New Delhi, India proudly announces the successful completion of Phase IV study on Akynzeo® I.V for Glenmark Pharmaceuticals ltd. As a CRO, CliniExperts provided end to end Clinical Support including Site Management and Clinical Operations support.

Study Title: An open label, single arm, multicenter, prospective study to evaluate safety and effectiveness of Akynzeo® I.V. [Fosnetupitant 235 mg and Palonosetron 0.25 mg (concentrate for solution for infusion)], in the Prevention of chemotherapy induced nausea and vomiting (CINV) in Indian patients (STOP-CINV study).

Study Design:

- 178 adult patients (male or female) aged >=18 and

Tags :

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles